8-K: Candel Therapeutics Announces Positive Final Survival Data for CAN-2409 in Pancreatic Cancer Phase 2 Trial

Candel Therapeutics reports positive final overall survival data from its Phase 2 trial of CAN-2409 in non-metastatic pancreatic cancer, showing a significant improvement in survival compared to the control group.

Summary

• Candel Therapeutics announced positive final overall survival data from its randomized controlled Phase 2 clinical trial of CAN-2409 in patients with borderline resectable pancreatic ductal adenocarcinoma (PDAC).
• The trial showed an estimated median overall survival of 31.4 months in the CAN-2409 group (n=7) compared to 12.5 months in the control group (n=6).
• Median survival post-progression was 21.2 months in patients who received CAN-2409 compared to 7.2 months in the control arm.
• Three out of seven patients who received CAN-2409 were still alive at the data cut-off, with survival times of 66.0, 63.6, and 35.8 months after enrollment.
• Previous analysis at 24 months showed survival rates of 71.4% in patients treated with CAN-2409 compared to 16.7% in the control group.
• CAN-2409 continued to be associated with a favorable safety/tolerability profile, with no dose-limiting toxicities or cases of pancreatitis.

Sentiment

Score: 8

Explanation: The document presents positive clinical trial results, indicating a significant improvement in survival rates for pancreatic cancer patients treated with CAN-2409. The favorable safety profile and potential for a late-stage trial contribute to a positive outlook.

Positives

• CAN-2409 showed a notable improvement in estimated median overall survival compared to the control group.
• The treatment was generally well-tolerated, with a favorable safety profile.
• Long-term survivors in the CAN-2409 arm experienced extended post-progression survival.
• Previous analyses showed higher survival rates at 24 months for patients treated with CAN-2409.
• CAN-2409 has received Fast Track Designation and Orphan Drug Designation from the FDA for the treatment of PDAC.

Risks

• The forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially.
• Final data from pre-clinical studies and completed clinical trials may differ materially from reported interim data from ongoing studies and trials.

Future Outlook

Based on the promising findings, the Company has decided to prepare for a larger, late-stage randomized controlled clinical trial of CAN-2409 in PDAC.

Management Comments

• W. Garrett Nichols, MD, MS, Candel's Chief Medical Officer, stated that CAN-2409 offers the potential to control pancreatic cancer and prolong survival.
• Paul Peter Tak, MD, PhD, FMedSci, CEO and President of Candel, highlighted the transformative potential of CAN-2409 in difficult-to-treat cancers.

Industry Context

The announcement highlights the ongoing efforts to develop effective treatments for pancreatic cancer, a disease with a poor prognosis, and positions CAN-2409 as a potential novel immunotherapy option.

Comparison to Industry Standards

• The median overall survival of 12.5 months in the control group aligns with historical survival rates for patients with borderline resectable PDAC receiving standard of care.
• The 31.4 months median overall survival in the CAN-2409 arm represents a significant improvement compared to standard of care, potentially positioning CAN-2409 as a best-in-class therapy if confirmed in larger trials.
• Competitors in the pancreatic cancer space include companies developing chemotherapies (e.g., Gemzar, Abraxane), targeted therapies (if applicable based on specific mutations), and other immunotherapies; however, CAN-2409's approach of in situ vaccination is unique.
• Comparable projects might include other Phase 2 or Phase 3 trials investigating novel therapies for PDAC, but the specific survival outcomes and safety profiles would need to be compared directly.

Stakeholder Impact

• Shareholders may react positively to the promising clinical trial results.
• Patients with pancreatic cancer may benefit from a potential new treatment option.
• The company's employees may be motivated by the positive progress of CAN-2409.

Next Steps

• The Company plans to prepare for a larger, late-stage randomized controlled clinical trial of CAN-2409 in PDAC.

Key Dates